Translate Bio
2010
FOUNDED
PUBLIC
STATUS
81-90
EMPLOYEES
TBIO
STOCK SYMBOL
1
INVESTMENTS
$9.20
SHARE PRICE
(As of Friday Closing)
Description
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Website
Formerly Known As
RaNA Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 29 Hartwell Avenue
- Lexington, MA 02421
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Translate Bio’s full profile, request a free trial.
Translate Bio Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $4.81 - $16.60 | $468M | $9.22 | -$3.16 | 225K | 50.9M |
Translate Bio Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 317,236 | 473,407 | ||
| Revenue | 2,894 | 1,420 | 0 | 0 |
| EBITDA | (112,757) | (101,442) | (77,620) | (26,082) |
| Net Income | (109,384) | (97,395) | (66,443) | (26,698) |
| Total Assets | 277,736 | 287,651 | 198,547 | 205,563 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Translate Bio Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Translate Bio‘s full profile, request access.
Request full access to PitchBookTranslate Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Translate Bio‘s full profile, request access.
Request full access to PitchBookTranslate Bio Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 000000000000 | Venture Capital-Backed | Houston, TX | 000.00 | 00000000000 | 000.00 | |
| 0000000 00000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 000000 0000000000 | Formerly VC-backed | Oslo, Norway | 00 | 00000 | 000000000 | 00000 |
| 00000 | Private Equity-Backed | San Diego, CA | 00 | 0000 | 0000000 0000 | 0000 |
Translate Bio Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 (000 0000000 | 04-Jan-2017 | 000000000 00000 00 | Biotechnology | 000000 000000 00. |
Translate Bio Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Translate Bio‘s full profile, request access.
Request full access to PitchBookTranslate Bio Executive Team (17)
6 Former Executives
You’re viewing 5 of 17 executives. Get the full list »Translate Bio Board Members (12)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Ankit Mahadevia MD | Atlas Venture | Board Member | 000 0000 | |
| Brian Gallagher Ph.D | SR One | Board Member | 000 0000 | |
| Daniel Lynch | Self | Chairman | 000 0000 | |
| Iain Dukes Ph.D | Self | Board Member | 000 0000 | |
| Joshua Resnick MD | Self | Board Member | 000 0000 |
6 Former Board Members
You’re viewing 5 of 12 board members. Get the full list »